EGFR Non-Small Cell Lung Cancer Market Forecast Highlights Expansion From $10.07 Billion To $13.74 Billion Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
EGFR Non-Small Cell Lung Cancer Market Growth From $10.07 Billion In 2026 To $13.74 Billion By 2030 At A CAGR Of 8.1%
The egfr non-small cell lung cancer market has witnessed robust growth in recent years. It is anticipated to expand from $9.34 billion in 2025 to $10.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historical growth can be ascribed to several factors, including the increasing prevalence of non-small cell lung cancer, advancements in molecular diagnostics, rising awareness of egfr mutation testing, the expansion of oncology specialty centers, and the increased availability of targeted therapies.
The egfr non-small cell lung cancer market is projected to experience substantial expansion in the coming years, reaching $13.74 billion by 2030, driven by an 8.1% compound annual growth rate (CAGR). This anticipated growth during the forecast period is largely due to a burgeoning pipeline of next-generation EGFR inhibitors, the increasing acceptance of precision oncology strategies, the broadened implementation of biomarker-driven treatment frameworks, the expanding incorporation of real-world data into oncology practice, and a heightened emphasis on patient-centered cancer care. Key trends expected over the forecast horizon encompass a greater uptake of targeted EGFR therapies, an increase in the utilization of companion diagnostic testing, a developing emphasis on tailored treatment pathways, the widening scope of combination therapy strategies, and a stronger incorporation of multidisciplinary cancer management.
Download A Free Sample Report For Comprehensive Market Insights:
EGFR Non-Small Cell Lung Cancer Market Expansion Supported By Key Demand Factors
A growing emphasis on personalized medicine methods is anticipated to boost the epidermal growth factor receptor (EGFR) non-small cell lung cancer market moving forward. Personalized medicine is a medical practice that adapts prevention, diagnosis, and treatment plans according to an individual’s genetic, environmental, and lifestyle factors. The adoption of personalized medicine strategies is increasing due to enhanced access to genetic and molecular profiling, which allows for the precise identification of disease-specific targets and permits treatments to be customized for improved patient outcomes. These personalized medicine approaches assist in managing epidermal growth factor receptor (EGFR) non-small cell lung cancer by identifying specific EGFR mutations in patients, thereby enabling physicians to prescribe targeted therapies that maximize efficacy while minimizing adverse effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA cleared 16 new personalized therapies for patients suffering from rare diseases in 2023, marking a significant increase from the six approvals observed in 2022. As a result, the heightened attention on personalized medicine techniques is driving the expansion of the epidermal growth factor receptor (EGFR) non-small cell lung cancer market.
EGFR Non-Small Cell Lung Cancer Market Segment Analysis: What Are The Major Market Categories?
The egfr non-small cell lung cancer market covered in this report is segmented –
1) By Drug Type: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Late Phase
2) By Mutation Type: Exon 19 Deletions; Exon 21 L858R Substitution Mutations; Exon 20 Insertion Mutations; Other Mutation Types
3) By Treatment Type: Monotherapy; Combination Therapy
4) By Route of Administration: Oral; Intravenous
5) By End User: Hospitals; Specialty Oncology Centers; Cancer Research Institutes; Academic Institutes; Other End Users
Subsegments:
1) By Tyrosine Kinase Inhibitors: First Generation Tyrosine Kinase Inhibitors; Second Generation Tyrosine Kinase Inhibitors; Third Generation Tyrosine Kinase Inhibitors
2) By Monoclonal Antibodies: Anti Epidermal Growth Factor Receptor Monoclonal Antibodies; Dual Target Monoclonal Antibodies; Antibody Drug Conjugates
3) By Late Phase: Patritumab Deruxtecan; Other Late Phase Pipeline Therapies
EGFR Non-Small Cell Lung Cancer Market Growth Trends Influencing Competitive Dynamics
Leading firms within the epidermal growth factor receptor (EGFR) non-small cell lung cancer market are prioritizing the creation of novel therapies, including antibody drug conjugates, with the aim of enhancing treatment effectiveness while simultaneously lessening systemic side effects when contrasted with conventional chemotherapy. An antibody-drug conjugate (ADC) represents a therapeutic approach that combines a potent pharmaceutical agent with an antibody designed to target cancer, thereby enabling the drug to be delivered precisely to malignant cells, without affecting healthy cells. For example, in June 2025, AstraZeneca Plc, a UK-based biopharmaceutical company, revealed that Datroway (datopotamab deruxtecan or Dato-DXd) secured authorization in the U.S. for the treatment of adult patients suffering from locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who had previously received EGFR-targeted therapy and platinum-based chemotherapy. This specific use received expedited approval supported by the demonstrated objective response rate (ORR) and duration of response (DoR), with ongoing approval relying on corroboration of clinical advantages in a forthcoming study. The U.S. FDA issued the authorization after undergoing Priority Review and Breakthrough Therapy Designation. The ruling drew support from an analysis of a specific patient group within the TROPION-Lung05 Phase II trial, as well as further data from the TROPION-Lung01 Phase III trial.
EGFR Non-Small Cell Lung Cancer Market Leading Companies Driving Competitive Growth
Major companies operating in the egfr non-small cell lung cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca Plc, Bayer AG, Eli Lilly and Company, Takeda Pharmaceuticals Company Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd., Betta Pharmaceuticals Co. Ltd., ShanghAI Allist Pharmaceuticals Co. Ltd., Oric Pharmaceuticals Inc., Black Diamond Therapeutics Inc., G1 Therapeutics Inc., Dizal Pharmaceutical, ArriVent BioPharma Inc., and Cullinan Therapeutics Inc.
Access The Complete EGFR Non-Small Cell Lung Cancer Market Report:
EGFR Non-Small Cell Lung Cancer Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egfr non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
